Day: December 5, 2023

Company Announcement No. 1074 On 24 October 2023, we initiated a share buyback programme, as described in Company Announcement No. 1066. According to the programme, the company will in the period from 24 October 2023 until 31 January 2024 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The following transactions have been recorded under the programme:Trading day Trading platform   Number of shares...

CALGARY, Alberta, Dec. 05, 2023 (GLOBE NEWSWIRE) — Prospera Energy Inc. (“Prospera” or the “Company”) (TSX.V: PEI, OTC: GXRFF, FRA: OF6B, OF6B.SG, OF6B.F, OF6B.BE). Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF, FRA: OF6B) is a publicly traded energy company based in Western Canada, specializing in the exploration, development, and production of crude oil and natural gas. Prospera is continuing to execute the horizontal transformation and is attaining the expected results. Seven horizontals have been drilled with three more expected prior to year-end. Prospera also drilled the light oil slanted well, encountering structure and pay as anticipated. Accordingly, PEI anticipates achieving 2023 year-end exit rate of 1,800 boepd GORR Financing Prospera Energy Inc. is pleased to announce the successful completion of a $3,000,000 GORR financing....

Launch of new share buyback program according to the safe harbour method Based on the expected result for 2023 and a very strong solvency coverage, the Board of Directors of Alm. Brand A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 26 April 2023. The authority is valid until 30 April 2024 and covers up to 10% of the share capital. Alm. Brand A/S may purchase shares up to a maximum aggregate purchase price of DKK 250 million of which DKK 200 million is intended for a share buyback program and DKK 50 million is intended for employee share programs. PurposeThe purpose of the share buyback is to distribute earnings to shareholders and meet obligations relating to the Group’s employee share programs. At a General Meeting of Alm. Brand A/S, a resolution will be proposed that any shares not...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree abrdn European Logistics Income plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Broker to abrdn European Logistics Income plc(d)        Date dealing undertaken: 4th December 2023(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a...

On 4 December 2023 the Register of Legal Entities registered an increased authorized capital of AB Akola Group (hereinafter – “the Company“). Data on shares of the Company after the increase of the authorized capital is as follows:Share type Ordinary registered sharesISIN LT0000128092Nominal, EUR 0.29Total number of shares 167,170,481Authorised capital of the Company, EUR 48,479,439.49Own shares acquired by the Company, EUR 734,972Number of votes, calculating the quorum of the General meeting of the shareholders* 166,435,509*All shares of the Company grant equal rights, though the shares acquired by the Company are considered to be non-voting shares in accordance with Paragraph 4 of Article 27 of the Law on Companies of the Republic of Lithuania.Additional information: Mažvydas Šileika, CFO of AB Akola GroupMob....

  Louvain-La-Neuve, Belgium, December 5, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announced today a research collaboration agreement with the University of Kansas Medical Center (KUMC) to advance preclinical research into the use of ConformalFLASH®1 technology using an IBA Proteus®ONE2 machine. The preclinical evaluation will be focused on skin and muscular normal tissue sparing after proton FLASH irradiation. The two organizations published a joint abstract, “Experimental demonstration of 360nA FLASH proton beam current via synchrocyclotron using IBA Proteus®ONE,” during the Proton Therapy Co-Operative Group (PTCOG) Congress 2023, which took place in Madrid, Spain, in June. The...

EfTEN Real Estate Fund AS wishes to inform all investors of the fund’s financial calendar for the 2024 financial year. We plan to disclose financial results and organize the general meeting of shareholders according to the following schedule: 01/02/2024        Unaudited results for Q4 2023 and 12 months 2023 29/02/2024        Audited results for 2023 02/04/2024        General meeting of shareholders 25/04/2024        Q1 interim results 31/07/2024        Q2 interim results 24/10/2024        Q3 interim results Marilin Hein CFOPhone: 655 9515E-mail: marilin.hein@eften.ee  

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The...

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $275.0 million. The offering is expected to close on or about December 7, 2023, subject to the satisfaction of customary closing conditions. In addition, SpringWorks has granted the underwriters a 30-day option to purchase up to an additional 1,422,413 shares of its common stock...

Nokia CorporationStock Exchange Release5 December 2023 at 4:30 EET Nokia comments on AT&T vendor plans Espoo, Finland – Nokia has a wide-ranging relationship with AT&T, supplying products and services across wireless, wireline and other network technologies, alongside similar relationships with other major North American network operators. Nokia is aware of AT&T’s plans to commit to an Open RAN deployment in collaboration with other vendors over the next five years. As a result, Nokia now expects revenue from AT&T in Mobile Networks will decrease over the next 2-3 years. AT&T accounted for 5-8% of Mobile Networks net sales year-to-date in 2023. The already announced action Nokia is taking to reduce its cost base is expected to partially mitigate the impact of AT&T’s decision. Nokia expects Mobile Networks...